Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14882503 | 0.86 | BCHE (0.51) | BCHEMCHR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14884504 | 0.83 | BCHE (0.48) | BCHEMCHR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3113481 | 0.81 | MAPT (0.64) | BCHEMAPTMCHR1HRH3 | |
| SCHEMBL14537645 | 0.79 | SIGMAR1 (0.52) | BCHE | |
| SCHEMBL13248372 | 0.77 | BCHE (0.52) | BCHEMAPTMCHR1HRH3 | |
| SCHEMBL13248370 | 0.76 | HTR2A (0.44) | CYP2D6 | |
| SCHEMBL3123212 | 0.74 | MAPT (0.49) | BCHEMAPT | |
| SCHEMBL14884505 | 0.74 | BCHE (0.49) | BCHEMAPTMCHR1HRH3 | |
| SCHEMBL14640185 | 0.72 | HRH3 (0.69) | MAPTMCHR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3118612 | 0.71 | TAAR1 (0.52) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-8349898-B2 | Sigma-1 receptor ligands and methods of use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349898-B2 | Sigma-1 receptor ligands and methods of use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349898-B2 | Sigma-1 receptor ligands and methods of use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2010059711-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059711-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | SIGMAR1, OPRL1, OPRK1 | BCHE 2920/4885MAPT 1852/4885MCHR1 22/4885 |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | SIGMAR1, OPRL1, OPRK1 | BCHE 3231/4885MAPT 1569/4885MCHR1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.